Market capitalization | €256.59m |
Enterprise Value | €284.34m |
PER (TTM) P/E ratio | 14.17 |
EV/FCF (TTM) EV/FCF | 12.14 |
EV/Sales (TTM) EV/Sales | 2.65 |
P/S ratio (TTM) P/S ratio | 2.39 |
P/B ratio (TTM) P/B ratio | 5.74 |
Dividend yield | 6.36% |
Last dividend (FY24) | €1.36 |
As a Free StocksGuide user, you can view scores for all 6,947 stocks worldwide.
2 Analysts have issued a Pharmasgp Holding forecast:
2 Analysts have issued a Pharmasgp Holding forecast:
Dec '23 | |
Current assets | 63 63 |
Fixed assets | 68 68 |
Total Assets | 131 131 |
Dec '23 | |
Equity | 40 40 |
Debt capital | 92 92 |
Total Capital | 131 131 |
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PharmaSGP Holding SE engages in the manufacture of non-chemical, over-the-counter pharmaceutical products. Its product brands include RubaXX, Restaxil, FULMINAN, DESEO, Neradin, and TAUMEA. The company is headquartered in Gräfelfing, Germany.
Head office | Germany |
CEO | Natalie Weigand |
Employees | 89 |
Founded | 2012 |
Website | pharmasgp.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.